Opticyte, Inc. was recently announced as one of 61 medical technology start-ups to be selected for the MedTech Innovator 2023 Cohort. This year’s cohort was highly competitive, with only 5% of applicants accepted into the accelerator. Opticyte joins top medical device, digital health, and diagnostic companies from around the world in the four-month program.
MedTech Innovator is the world’s largest accelerator for medical devices and has completed 10 years of successful cohorts. From the accelerator’s portfolio to date, companies have received over 200 FDA approvals and clearances and secured over $6.8B in follow-on funding.
Lori Arakaki, CEO and co-founder of Opticyte, said, “Being part of this year’s MedTech Accelerator cohort is an honor and exciting opportunity for Opticyte. I am looking forward to meeting other pioneering entrepreneurs as well as the extensive slate of industry partners, investors, and advisors that MedTech Innovator has lined up for the program. I am eager to apply the mentorship and connections from the accelerator towards Opticyte’s bright future.”
The program kicks off this coming week in Silicon Valley where Dr. Arakaki will join leaders from the other cohort start-ups for networking and workshops. The accelerator companies will be featured at the June 16 WSGR Medical Device Conference in San Francisco, CA. At the conclusion of the program, all 61 companies will present at AdvaMed’s MedTech Conference in Anaheim, CA from October 9-11, 2023.
Learn more from the press release here: World’s Largest Medtech Accelerator Announces 61 Startups for its 2023 Cohort (yahoo.com)